TIMER analysis indicated that FMNL2 expression was negatively associated with ER-related molecular subtyping in breast cancer; FMNL2 was low-expressed in luminal subtyping, but highly expressed in basal subtyping of breast cancer tissues (Fig. 5A). The gene discussed is FMNL2; the disease is breast carcinoma.